Skip to primary navigation
Skip to main content
Skip to footer

Neurotech International

ASX:NTI

Home
Corporate
Development Programs
Investors
Contact

Break it Down: Neurotech’s human adult study tick of approval for cannabinoid drug

25 November 2024 News & Media

Read the full article here.

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1780509132anoit1780509132anret1780509132nihce1780509132torue1780509132n@ofn1780509132i1780509132

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*

First Last

Email*

Comments

This field is for validation purposes and should be left unchanged.

Copyright © 2026 Neurotech International • Site by White Noise Communications

Download prospectus